Annals of the Rheumatic Diseases Rheumatology
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment
The publisher did not provide an abstract — full text is available via the link below.